secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119406
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025
--------------------------------------------------------------------------------

- Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.
- Cash and equivalents $37.1M at March 31, 2025, down from $60.0M at Dec 31, 2024; Q1 cash burn $22.9M.
- Drew €10.0M tranche A of EIB loan on May 6; believes conditions met for €12.5M second tranche.
- Phase 3 trial primary endpoint (PFS) readout on track for Q3 2025; BLA submission planned in 2025.
- Enrollment completed in Phase 2 basket trial (IOB-032) for SCCHN/melanoma; initial data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/0001193125-25-119406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/d859516d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer